
One-Month Rebound of 70%, 3 Institutions File for ETFs: Decoding the Real Data Behind INJ's Surge
Author: Jamie, TechFlow
In the crypto space, very few projects can climb out of the previous cycle's "graveyard" twice.
For veteran retail traders who lived through the 2023–2024 market cycle, Injective ($INJ) was once a name that triggered massive FOMO. Back then, wearing the halo of an "on-chain derivatives public chain," it short-squeezed its way to a historical all-time high of $52.6 amid the backing of various market makers;
But during the long dead zone that followed, it also became one of the most devastated fallen stars; the price quietly drifted down to the $4 range earlier this year, wiping out over 85% of its market cap, leaving the community as quiet as a ghost town.
This situation created room for capital to revitalize older coins.
Today (October 16), INJ surged over 23% on heavy volume in a single day, with a bullish candle pushing it directly to $9.16; and if you zoom out the K-line chart, you’ll be surprised to find that over the past month when no one was paying attention, this "old demon coin" has quietly rallied nearly 70% from its bottom, with perpetual contract open interest spiking by $35 million in just a few days.

If you stretch out the timeline, you’ll see this is actually a carefully orchestrated narrative pump centered around "breaking through US regulatory hurdles for compliant ETFs + institutional RWA transition."
Ditching the Crypto Wild West Outfit, Moving the Table into the White House
The climax of this short squeeze rally came this Wednesday (October 14) in Washington, D.C.
That day, Injective Co-founder and CEO Eric Chen, dressed sharply in a suit, visited officials at the White House, the U.S. Securities and Exchange Commission (SEC), and the Commodity Futures Trading Commission (CFTC) alongside his company’s General Counsel and head of policy.
News trickled back to the crypto circle, bulls grew excited, and crypto Twitter (CT) began viewing it as a positive step toward mainstream compliance.
In the crypto world, founders going to Washington to "network" isn't rare; what's unusual is that this time, when Chen knocked on doors, he actually held several regulatory trump cards that earned Wall Street's respect.
Looking back at the two-month timeline, you'll realize the Injective team has been quietly working on one thing:
Transforming the old "casino base" that relied on retail trading in altcoin perpetuals into an "institutional RWA-focused chain" backed by the U.S. government.


- First, on August 19 this year, an institutional service entity under Injective quietly obtained official registration as a Transfer Agent with the SEC.
This license carries immense weight, meaning it is legally authorized to record ownership of on-chain tokenized securities and process dividends.
- Next, in September and early October, three institutions—21Shares, Canary Capital, and REX-Osprey—lined up to submit applications to the SEC for INJ spot and staking ETFs; notably, Canary aggressively proposed using 90% of the INJ in the ETF for on-chain staking to earn yields.
- Yesterday, October 15, just the day after the CEO left the White House, Canadian publicly traded mortgage giant Pineapple Financial announced its rebranding to Pentiv and declared plans to migrate its entire $10 billion real estate mortgage portfolio onto the Injective chain.
Meanwhile, on-chain technical parameters are being tightly aligned with this "institutional narrative."
The IIP-709 governance proposal currently being voted on by Injective this week is expected to conclude tomorrow, decisively switching order placement and cancellation operations in the exchange module to fixed gas fees.
Retail traders might barely notice fraction-of-a-cent fluctuations in gas fees, but for traditional high-frequency market makers executing tens of thousands of orders daily, reducing transaction friction costs is likely the crucial trust-building signal they needed before entering the market.
So you see, from the SEC license and three ETF applications, to hundreds of millions in mortgages moving on-chain, institution-tailored fixed gas fees, and finally walking into the White House and SEC offices...
With this combination of moves, the narrative has shifted. The old INJ that used to trade on concepts is now donning a full suite of Wall Street-compliant suits.
Pumping Another Narrative: "Real Revenue Is Undervalued"
If the aforementioned regulatory background doesn't directly boost the token price, then the chart INJ's official account posted yesterday serves more as an implicit message: as a crypto project, it generates real revenue and is undervalued relative to its market cap.
In this chart tallying figures from 2026 to date, Injective's "Protocol Revenue to Fully Diluted Valuation (Revenue/FDV)" ratio stands at a staggering 0.95, ranking first among all major public chains on the network.
Trailing behind it are Solana (0.83) and Arbitrum (0.78).

From a revenue perspective, this ratio on paper means INJ's current market cap is relatively small, implying greater room for upside potential. Coupled with INJ's buyback program, it's easy to interpret these figures as a bullish signal.
However, I believe this is more of a semantic game.
"Revenue/FDV" is a deceptively simple division formula. To rank first, either your numerator (real revenue) must be astonishingly huge, or your denominator (FDV) must have crashed sufficiently.
Injective's top ranking relies entirely on the latter.
If you check the raw ledger data from Token Terminal and LunarCrush, you'll find Injective's actual on-chain protocol revenue over the past year is merely about $6 million, with cumulative fees over three years totaling only $5.9 million—ranking outside the top ten on the absolute profitability list for major L1 public chains; less than a fraction of Ethereum's ($3.8 billion) or Solana's ($1.6 billion).
The sole reason it dominates the "revenue-to-valuation ratio" is because its token price plummeted 85% over the past two years, crushing its FDV denominator down to a mere $800–900 million.
Comparing a shrunken sub-$1 billion float against a multi-hundred-billion-dollar Ethereum "break-even rate" is essentially a highly sophisticated numbers-driven PR game.
More intriguingly, in the comments section of CoinGecko's tweet today announcing INJ's gains, a seasoned trader directly posted a screenshot from the Cosmos block explorer Mintscan, piercing another veil:
"Why do all major market data sites state that INJ's maximum supply is 100 million tokens and fully circulating, while Mintscan shows the actual on-chain total supply has already reached 123 million?"
This is the rarely discussed flip side behind many tokens' deflationary mechanisms:
Although Injective loudly conducts monthly buybacks and burns, as a PoS public chain, it continuously mints new tokens at a dynamic inflation rate to maintain node security and high staking yields.
Therefore, it's highly possible that the modest $6 million in on-chain real revenue earmarked for burning simply can't outpace the speed at which the staking minting machine pumps out new coins.
An Old Tree Blooming Afresh: How Far Can It Go?
Placing the bullish narrative alongside on-chain data, the logic behind INJ's nearly 70% surge in a single month becomes crystal clear:
Severely oversold with a small float, primed for a pump via regulatory narratives.
Even if its actual on-chain revenue remains lean, hot money and sidelined derivative funds are likely to rush in, pumping out sequential short-squeeze green candles in the short term. With the vote on the aforementioned IIP-709 fixed gas fee proposal concluding tomorrow, short-term bullish sentiment may continue to battle back and forth above the $9 level.
But for retail investors, the true value of understanding this "White House makeover" lies in applauding the team's top-tier government relations and trading execution skills, without ever mistaking the seemingly attractive revenue/FDV ratio as a reason to FOMO in.
Until more market-cap-positive catalysts materialize, short-term focus should instead be on chip structure, such as changes in open interest and funding rates, as well as whale deposit/withdrawal behaviors surrounding INJ on-chain.
After all, revitalizing older coins is the meta in this market cycle, and we shouldn't rule out more legacy tokens rallying on the back of similar regulatory narratives. INJ is just one of them, and certainly not the only one.















